@article{ref1,
title="The effects of bifemelane hydrochloride on depressive illness of the elderly",
journal="International journal of clinical pharmacology research",
year="1995",
author="Yamagami, S. and Koide, S. and Mui, K. and Perk, S. and Hirayama, E. and Kioka, T. and Soejima, K. and Inoue, K. and Nishiwaki, S.",
volume="15",
number="1",
pages="1-7",
abstract="The therapeutic efficacy, utility and safety of bifemelane hydrochloride were studied in 52 elderly depressive patients. The drug was administered as a tablet containing 50 mg orally three times daily for 8 consecutive weeks. The final global improvement rating and global utility rating were respectively 80.8 and 73.1 percent for all patients. The improvement rates on the Hamilton depression rating scale (HAM-D) were more than 60% for depressed mood, guilt, suicide, middle insomnia, delayed insomnia, psychotic anxiety, gastro-intestinal symptom, hypochondriasis, depersonalization and derealization. The rates regarding global symptoms evaluated by the Psychoneurotic rating scale for doctor's use were more than 60% for tension, agitation, irritability and excitement, phobia, depression, hypochondria and nocturnal delirium in psychotic symptoms, and insomnia in addition to palpitation in somatic symptoms. A significant decrease was also observed in the symptoms covered by the Self-rating depression scale of Zung after treatment with this drug. There were no instances of side-effects, nor any abnormalities in laboratory tests, encountered throughout the trial. Therefore, bifemelane hydrochloride is of value for the treatment of geriatric depression.<p /><p>Language: en</p>",
language="en",
issn="0251-1649",
doi="",
url="http://dx.doi.org/"
}